

Solid State Physics and Perturbed Angular Correlations at ISOLDE

new tools, new ideas, new people



UNIVERSITÄT
DES
SAARLANDES

UNIVERSITÄT
**DUISBURG
ESSEN**

Juliana Schell
Universität des Saarlandes -> Universität Duisburg Essen & ISOLDE-CERN

EXOTIC

Presenting a review of today's offer at:

- **Nuclear physics and Astrophysics**
- **Material's science**
- **Bio-physics**
- **Life sciences**
- What is **WORKING** and **NEW...**
- What is **USEFUL** and ... **USABLE**
- Who are the **USERS** ...
- **Where** ...

... aiming to work better in 10 – 15 years !

KEY Features for Sustainability of RIB Applications

ADVANTAGES → SENSITIVITY / TRACEABILITY:

Very low concentrations of radioactive impurity atoms in materials.
surfaces or in

ADVANTAGE

Element trans
decay add ch
spectroscopy
photolumine
deep level tr
spectroscopy

SUSTAINABILITY !!!!!!!

...Yes but under conditions ...

Originality & Uniqueness of Science output

Large panoply of Elements and isotopes

Variety, Intensity and Purity

! CONCENTRATION OF EFFORTS !

e-, β -, β +, α Emission Channeling
direct and precise lattice site location.


pick the right isotope to have TUNEABLE RANGE OF ENERGY DEPOSITION :
Different isotopes and decay particles can adapt to tumor or tumor cell killing.

ISOL (ISOLDE EURISOL)

Isotope Separator

ON-Line

driver-beam




Third Thick HOT ISOL target

Isotope Separator ON-LINE – ISOL:

Such an instrument is essentially a **target**, **ion source** and an **electromagnetic mass analyzer** coupled in series. The apparatus is said to be on-line when the material analyzed is directly the target of a **nuclear bombardment**, where reaction products of interest formed during the irradiation are slowed down and **stopped** in the system.


H. Ravn and B. Allardyce, 1989, Treatise on heavy ion science

Isotope Separator On-Line ISOL - facilities 1967



Radioactive Ion Beam – facilities Worldwide 2013


- Existing and in preparation




• **ISOLDE: CERN's longest running facility**

The ISOL Process


Production





Extraction/Ionization



Isotope Separation




Post acceleration or Experiment




Fast, Efficient, Universal and Selective!


Target handling

Ion energy: 20-60keV






The atomic
line spectra are
the
element's
fingerprint



RILIS in action

Gammmas singles

Laser Cd ionization




Energy (keV)





public

6 mSv/y – B workers


20 mSv/y – A workers



1 Gy = 1 J/Kg leads to a temperature increase of only $2.4 \cdot 10^{-4}$ °C



SSP @ ISOLDE: Diverse community



1 32

Running experiments/letters of intent	24
Participating countries	26
Scientists	160

Current and PROSPECTIVE Work using EXOTIC Radioactive isotopes

→ THINKING Materials and Molecular Properties ←

dealing with mass, electromagnetism, many body systems and scaling
Atomic-like information is the aim !

→ Semiconductor Physics (Si, Oxides, organic compounds)

→ Multi- ferroic- magnetic

→ Nanomaterials (geometry, downsizing and integration)

→ Surfaces and interfaces (bulk properties are modified)

→ Soft matter : graphen,

→ Bio / Molecular chemistry and physics

→ THINKING Life Sciences ←

optimizing delivering and range of deposition of highly concentration of energy upon radioactive decay into the living body or cell of interest.

Enlarging the choices of radioisotopes is the aim !

→ NEW isotopes and decay modes for diagnosis and treatments.

RECENT DEVELOPMENTS


Material's Science Applications




a commitment for the future based on facts !

On-line diffusion chamber at ISOLDE

2011




^{61}Cu (3.3h) diffusion in Cd saturated CdTe



Isotope	$t_{1/2}$	Detection
^{38}Cl	37.3 min	β^- 4800keV ; γ 2168keV
^{11}C	20.38 min	β^+ ; γ 511keV
^{13}N	9.96 min	β^+ ; γ 511keV
(^{15}O)	122 s	β^+ ; γ 511keV
^{29}Al	6.6 min	γ 1273keV

Unknown Aluminum self diffusion



(T.G.Stoebe *et al.*, Phys. Rev. 166 (1968) 621)

- ◆ Single stable Al isotope: no SIMS measurements
- ◆ Unknown activation energy of self diffusion in Al
- ◆ Unknown role of vacancies, di-vacancies at different temperatures.
- ◆ Unknown Al diffusion in Al-based compounds

From the Avogadro Project : define Kg in terms of number of Si atoms...

$$N_A = \frac{V_{\text{mol}}}{V_0} \cdot$$

28Si

$$N_A = \frac{V_{\text{mol}}}{(a^3/n)},$$

$$N_A = \frac{M_{\text{Si}}}{m} \frac{V}{(a^3/8)},$$

Scientific American
295, 102 – 109 (2006)



LASER

HeCd	(3,8 eV)
Nd:YAG	(2,3 nm)
Diode	(1,9 nm)

Cryostat

He-Bathcryostat (1,5 – 300 K) Closed cycle

experimental tool for studying electrically active defects and concentration in semiconductors.

... to measure optical properties of mono-isotopic Si!

Photo Luminescence – PL Deep Level Transient Spectroscopy (DLTS)




Monochromator

Focus: 0,75 m
Gratings: 150 – 1800 l/mm

Detectors

CCD-camera (1,1 - 6,2 eV)
Ge-Diode (0,7 - 1,5 eV)

JOURNAL OF APPLIED PHYSICS




*Photoluminescence of deep defects involving transition metals in Si:
New insights from highly enriched ^{28}Si*
by M. Steger, A. Yang, T. Sekiguchi et al.



AIP

Hg195 9.9 h 1/2- EC	Hg196 0+ * 0.15	Hg197 64.14 h 1/2- EC	Hg198 0+ * 9.97
Au194 38.02 h 1- EC	Au195 186.09 d 3/2+ EC	Au196 6.183 d 2- β^-	Au197 3/2+ 100
Pt193 50 y 1/2- EC	Pt194 0+ * 32.9	Pt195 1/2- * 33.8	Pt196 0+ * 25.3


777meV feature, now shown to include Pt and 4 Cu atoms!



Emission Channeling of decay particles, on single crystals $(\beta^-$, β^+ , c.e., α)



Hyperfine Interactions with Mossbauer spectroscopy



Development of ^{57}Mn beam in late 1990s (with laser ionisation) brought about a new era in Mossbauer experiments at ISOLDE.

- Very clean, intense beam of ^{57}Mn ($>3 \times 10^8 \text{ ions sec}^{-1}$)
- **Allows collection of single Mossbauer spectrum in ~ 3 mins.**
- Able to collect many hundreds over course of a 3 day run.
- **Allows low concentrations of probe atoms to be used ($\sim 10^{-4}\text{At\%}$)**

Fe: ZnO a ferromagnetic semiconductor? (nope!)



6 fold spectrum: characteristic of magnetic structure (at room temperature!!!).

DOGRA, R.; CARBONARI, A. W.; MERCURIO, M. E.; CORDEIRO, M. R.; RAMOS, J. M.; SAXENA, R. N.


Search for Room Temperature Ferromagnetism in Low-Concentration Transition Metal Doped ZnO Nanocrystalline Powders Using a Microscopic Technique.

IEEE Transactions on Magnetics, v. 46, p. 1780-1783, 2010

After high-dose implantations, precipitates of Fe-III are formed. These form clusters yielding misleading information about the nature of magnetism in ZnO (as reported by many groups over the last number of years).



PAC results: no DMS at RT!!!!



No magnetic interactions observed under the measurements conditions
for intrinsic and doped SnO₂ or TiO₂

PAC reveals the presence of two different EFGs for each case: $^{111m}\text{Cd}(^{111}\text{Cd})$, $^{181}\text{Hf}(^{181}\text{Ta})$, $^{117}\text{Cd}(^{117}\text{In})$ and $^{111}\text{In}(^{111}\text{Cd})$, which are assigned to different local environments.

We stress the particular cases of $^{181}\text{Hf}(^{181}\text{Ta})$ and $^{111}\text{In}(^{111}\text{Cd})$, where a major fraction, $f_1 = 55\text{-}80\%$, of probe atoms was assigned to substitutional Sn/Ti sites in the Sn/TiO₆ octahedral [Schell, J., CERN-THESSIS-2015-229].





RECENT DEVELOPMENTS

Bio-physics applications




a commitment for the future based on facts !


Perturbed angular correlation (PAC) Spectroscopy applied to BIOPHYSICS



Fourier transform



Least χ^2 analysis




$$A_{22}G_{22}(t) = 2 \frac{W(180^\circ, t) - W(90^\circ, t)}{W(180^\circ, t) + 2W(90^\circ, t)}$$




6·180° spectra and 24·90° spectra

ω_Q and η
+
BASIL model
QM calculations



^{111m}Cd PAC (48M) - De novo designed heavy metal Ion binding proteins: ns dynamics

IS488



50 °C

35 °C



20 °C

1 °C

1 °C

-20 °C

-196 °C



Temp [°C]	τ_1 [ns]	τ_{-1} [ns]
1	52	48
20	42	36
35	28	20
50	19	12


Stachura et al. Manuscript Science in preparation

In vivo experiments Hg(II) binding to barley 199mHg PAC (42M)

IS488



Adolph et al. *Chem. Eur. J.*, 2009, 15, 7350 – 7358



- 5-7 days-old plants
- Plant inserted into test tube.
- Fast uptake of Hg(II) (<1h)
- Bound to large molecules,
similarities to HgS_2 compounds

RECENT DEVELOPMENTS

Life Science applications



a commitment for the future based on facts !


Radionuclides for diagnosis and therapy

SPECT


PET

Therapy


IS528



Immunology approach



Multidisciplinary collaboration to fight cancer



Immunology


Structural biology

Coordination
chemistry

Nuclear physics
and
radiochemistry

Radionuclides for therapy

Radio-nuclide	Half-life	E mean (keV)	E γ (B.R.) (keV)	Range
Y-90	64 h	934 β	-	12 mm
I-131	8 days	182 β	364 (82%)	3 mm
Lu-177	7 days	134 β	208 (10%) 113 (6%)	2 mm



Established isotopes

Emerging isotopes

localized radiation

Production of non-carrier-added ^{177}Lu

Hf 176 5.26	Hf 177 51 m 1.1 s 18.60	Hf 178 31 a 4.0 s 27.28	Hf 179 25 d 18.7 s 13.62	Hf 180 5.5 h 35.08
σ_{23}	γ 277; 295; 327... γ 208; 229; 379... $\sigma_{10^{-7}}$ σ_{45} σ_{375}	γ 574; 495; 217... γ 426; 326; 213; $\sigma?$ σ_{32}	γ 454; 363; 123; γ 214 σ_{46}	γ 332; 443; 215; 57... β^- σ_{13} $\sigma_{n,\alpha}$ $\sigma_{<1.3 \cdot 10^{-10}}$
Lu 175 97.41	Lu 176 2.59	Lu 177 160.1 d 6.71 d	Lu 178 22.7 m 28.4 m	Lu 179 4.6 h
σ_{16+8}	β^- 3.68 h 1.2...; 1.3...; ϵ γ 307; 202; 88... σ_{2+2100}	β^- 0.2... γ 414; 319; 122... $\sigma_{3.2}$	β^- 0.5... γ 208; 113... σ_{1000}	γ 193; 1341; 1310; γ 214... σ_{g}
Yb 174 31.83	Yb 175 4.2 d	Yb 176 12 s 12.76	Yb 177 6.5 1.9 h	Yb 178 74 m
σ_{63} $\sigma_{n,\alpha} < 0.00002$	β^- 0.5... γ 396; 283; 114... $\sigma_{n,\alpha} < 1E-4$	γ 293; 390; 190... 96... $\sigma_{n,\alpha} < 1E-4$	β^- 1.4... γ 104; 228 σ_{g}	β^- 1.4... γ 150; 1080; 122... 1241... σ_{g}



Irradiation in high flux reactor (e.g. ILL Grenoble),
then chemical separation of ^{177}Lu from stable Yb.




Male

36 years of age

Small cell pancreatic
neuroendocrine
tumour

Liver metastases

Ki-67 index 10-15%
(liver biopsy)



4 cycles with ^{177}Lu -
octreotate and
capecitabine

Partial remission


Roelf Valkema, EANM-2008.

4th therapy

1st therapy

Radionuclides for therapy

Radio-nuclide	Half-life	E mean (keV)	E_γ (B.R.) (keV)	Range
Y-90	64 h	934 β	-	12 mm
I-131	8 days	182 β	364 (82%)	3 mm
Lu-177	7 days	134 β	208 (10%) 113 (6%)	2 mm
Tb-161	7 days	154 β 5, 17, 40 e^-	75 (10%)	2 mm 1-30 μm
Tb-149	4.1 h	3967 α	165,...	25 μm
Ge-71	11 days	8 e^-	-	1.7 μm
Er-165	10.3 h	5.3 e^-	-	0.6 μm



cross-fire

Established isotopes

Emerging isotopes

R&D isotopes:
supply-limited!

localized

Modern, better targeted vectors require shorter-range radiation
 ⇒ need for adequate (R&D) radioisotope supply.

Radioisotopes for targeted alpha therapy

Radio-nuclide	Half-life (h)	Advantage	Problem
Tb-149	4.12	Known (bio)chemistry	Availability
Pb-212	10.6	Availability (recycled from U-fuel ^{228}Th)	Release of daughter?
Bi-212	1.01	Known (bio)chemistry Availability	Short half-life
Bi-213	0.76	Known (bio)chemistry	Short half-life Availability
At-211	7.22	Half-life	Challenging (bio)chemistry
Ra-223	274	Half-life Availability	Only for bone metastases (similar chemistry to Ca)
Ac-225	240	Half-life Known (bio)chemistry	Release of daughters? Availability

Terbium: a unique element for nuclear medicine




Dy 150 7.2 m $\epsilon: \beta^+$ $\alpha: 4.23$ $\gamma: 387$ $\sigma: 3.99$ $\tau: 1.79$ $\lambda: 390$ $\mu: 186$	Dy 151 17 m $\epsilon: \alpha: 4.07$ $\gamma: 386; 49;$ $546; 176...$ $\sigma: 3.63$ $\tau: 257$ $\lambda: 0$	Dy 152 2.4 h $\epsilon: \beta^+$ $\alpha: 3.46$ $\gamma: 81; 214;$ $100; 254$ $\sigma: 3.63$ $\tau: 257$ $\lambda: 0$	Dy 153 6.29 h $\epsilon: \beta^+$ $\alpha: 3.46$ $\gamma: 81; 214;$ $100; 254$ $\sigma: 2.87$	Dy 154 $3.0 \cdot 10^6$ a $\epsilon: \beta^+$ $\alpha: 0.9$ $\gamma: 227...$ $\sigma: 2.87$	Dy 155 10.0 h $\epsilon: \beta^+$ $\alpha: 0.9; 1.1...$ $\gamma: 227...$ $\sigma: 0.056$	Dy 156 0.056 $\epsilon: \beta^+$ $\alpha: 0.009$ $\gamma: 326...$ $\sigma: 0.056$	Dy 157 8.1 h $\epsilon: \beta^+$ $\alpha: 0.009$ $\gamma: 326...$ $\sigma: 0.095$	Dy 158 0.095 $\epsilon: \beta^+$ $\alpha: 0.006$ $\gamma: 58; \alpha^-$ $\sigma: 8000$	Dy 159 144.4 d $\epsilon: \beta^+$ $\alpha: 0.0003$ $\gamma: 50$ $\sigma: 600$ $\tau: \alpha < 1E-6$	Dy 160 2.329 $\epsilon: \beta^+$ $\alpha: 0.0003$ $\gamma: 50$ $\sigma: 600$ $\tau: \alpha < 1E-6$	Dy 161 18.889 $\epsilon: \beta^+$ $\alpha: 0.0003$ $\gamma: 600$ $\sigma: 600$ $\tau: \alpha < 1E-6$	Dy 162 25.475 $\epsilon: \beta^+$ $\alpha: 1.70$
Tb 149 4.2 m $\epsilon: \beta^+$ $\alpha: 3.97$ $\gamma: 3.97$ $\sigma: 3.99$ $\tau: 1.58$ $\lambda: 390$ $\mu: 186$	Tb 150 5.8 m $\epsilon: \beta^+$ $\alpha: 3.71$ $\gamma: 635$ $\sigma: 3.7$ $\tau: 100$ $\lambda: 390$ $\mu: 186$	Tb 151 25 s $\epsilon: \beta^+$ $\alpha: 3.71$ $\gamma: 49$ $\sigma: 3.41$ $\tau: 100$ $\lambda: 390$ $\mu: 186$	Tb 152 42 m $\epsilon: \beta^+$ $\alpha: 3.49$ $\gamma: 349$ $\sigma: 3.49$ $\tau: 100$ $\lambda: 390$ $\mu: 186$	Tb 153 17.5 h $\epsilon: \beta^+$ $\alpha: 3.41$ $\gamma: 250$ $\sigma: 3.41$ $\tau: 100$ $\lambda: 390$ $\mu: 186$	Tb 154 2.34 d $\epsilon: \beta^+$ $\alpha: 3.41$ $\gamma: 250$ $\sigma: 3.41$ $\tau: 100$ $\lambda: 390$ $\mu: 186$	Tb 155 5.32 d $\epsilon: \beta^+$ $\alpha: 3.41$ $\gamma: 250$ $\sigma: 3.41$ $\tau: 100$ $\lambda: 390$ $\mu: 186$	Tb 156 5.32 d $\epsilon: \beta^+$ $\alpha: 3.41$ $\gamma: 250$ $\sigma: 3.41$ $\tau: 100$ $\lambda: 390$ $\mu: 186$	Tb 157 99 a $\epsilon: \beta^+$ $\alpha: 5.4$ $\gamma: 54$ $\sigma: 5.4$ $\tau: 5.4$ $\lambda: 54$ $\mu: 54$	Tb 158 99 a $\epsilon: \beta^+$ $\alpha: 5.4$ $\gamma: 54$ $\sigma: 5.4$ $\tau: 5.4$ $\lambda: 54$ $\mu: 54$	Tb 159 100 $\epsilon: \beta^+$ $\alpha: 1.7$ $\gamma: 879; 299;$ $966...$ $\sigma: 570$	Tb 160 72.3 d $\epsilon: \beta^+$ $\alpha: 1.7$ $\gamma: 879; 299;$ $966...$ $\sigma: 570$	Tb 161 6.90 d $\epsilon: \beta^+$ $\alpha: 0.5; 0.6...$ $\gamma: 26; 49; 75...$ $\sigma: 570$
Gd 148 74.6 a $\epsilon: \beta^+$ $\alpha: 3.183$ $\sigma: 14000$	Gd 149 9.28 d $\epsilon: \beta^+$ $\alpha: 3.016$ $\gamma: 150; 299;$ $347...$	Gd 150 $1.8 \cdot 10^6$ a $\epsilon: \beta^+$ $\alpha: 2.60$ $\gamma: 154; 243;$ $175...$	Gd 151 120 d $\epsilon: \beta^+$ $\alpha: 2.14; \gamma: 700$ $\sigma: 0.007$	Gd 152 0.20 $\epsilon: \beta^+$ $\alpha: 2.14; \gamma: 700$ $\sigma: 0.007$	Gd 153 239.47 d $\epsilon: \beta^+$ $\alpha: 2.18$	Gd 154 2.18 $\epsilon: \beta^+$ $\alpha: 2.18$	Gd 155 14.80 $\epsilon: \beta^+$ $\alpha: 2.18$	Gd 156 20.47 $\epsilon: \beta^+$ $\alpha: 2.18$	Gd 157 15.65 $\epsilon: \beta^+$ $\alpha: 2.18$	Gd 158 24.84 $\epsilon: \beta^+$ $\alpha: 2.18$	Gd 159 18.48 h $\epsilon: \beta^+$ $\alpha: 2.18$	Gd 160 21.86 $\epsilon: \beta^+$ $\alpha: 2.18$
Gd 148 74.6 a $\epsilon: \beta^+$ $\alpha: 3.183$ $\sigma: 14000$	Gd 149 9.28 d $\epsilon: \beta^+$ $\alpha: 3.016$ $\gamma: 150; 299;$ $347...$	Gd 150 $1.8 \cdot 10^6$ a $\epsilon: \beta^+$ $\alpha: 2.60$ $\gamma: 154; 243;$ $175...$	Gd 151 120 d $\epsilon: \beta^+$ $\alpha: 2.14; \gamma: 700$ $\sigma: 0.007$	Gd 152 0.20 $\epsilon: \beta^+$ $\alpha: 2.14; \gamma: 700$ $\sigma: 0.007$	Gd 153 239.47 d $\epsilon: \beta^+$ $\alpha: 2.18$	Gd 154 2.18 $\epsilon: \beta^+$ $\alpha: 2.18$	Gd 155 14.80 $\epsilon: \beta^+$ $\alpha: 2.18$	Gd 156 20.47 $\epsilon: \beta^+$ $\alpha: 2.18$	Gd 157 15.65 $\epsilon: \beta^+$ $\alpha: 2.18$	Gd 158 24.84 $\epsilon: \beta^+$ $\alpha: 2.18$	Gd 159 18.48 h $\epsilon: \beta^+$ $\alpha: 2.18$	Gd 160 21.86 $\epsilon: \beta^+$ $\alpha: 2.18$



CERN-MEDICIS: Medical isotopes collected from ISOLDE

R. Catherall, M. Dias, T. Giles, Z. Lawson, S. Marzari, T. Stora (CERN)

Dr. Forni (Clin. Carouge), L. Vouga, Prof. P. Morel, Prof. L. Buehler, Prof. Y. Seimbille, Prof. O. Ratib (HUG, Geneva), Prof. D. Hanahan (ISREC-EPFL, Lausanne), Prof. J. Prior, Dr. F. Buchegger (CHUV, Lausanne), Prof. M. Huyse, Prof. P. van Duppen (Univ. Leuven), Prof. S. Lahiri (SINP, Kolkata)





Irradiation station commissioned with beam


HOOLDE



Medicis



*Tests with protons:
Done successfully !*



Thierry.Stora@cern.ch

The (potential) role of ISOL in nuclear medicine

1. Samples of R&D isotopes which are not commercially available or easily producible by other means.
2. Isotopes with ultimate specific activity for R&D, e.g. studies of efficacy versus specific activity.
3. Isotopes that are best produced by spallation (^{149}Tb ,...).

Existing ISOL beams are sufficiently intense for preclinical studies, in certain cases even for clinical studies.

How to organize R&D with RIBs in nuclear medicine?

**Physicists are used to “travel to the isotopes”,
but isotopes must “travel to physicians and patients”.**

CONCLUSIONS

“SSP” of EXOCTIC radioactive isotopes

- ❖ Specific areas are identified:

Life Sciences

Materials

Nuclear

Chemistry...

- ❖ The methods follow the needs with progressing quality...

- ❖ Viability and Visibility of “Applications”

depend at the long term from diversifying and optimizing
RIB infrastructures with:

Dedicated BEAM TIME and BEAM LINES

Dedicated LABORATORY SPACE

**...the future of “Applications” depend very much on the concept
of the next generation of RIB facilities**

Acknowledgments

To the



organizers !

... to colleagues and collaborators!

- R. Vianden
- D. C. Lupascu
- M. Deicher
- A. Fenta
- H. Gunnlaugsson
- T. E. Molholt
- K. Johnston
- L. B. S. Hemmingsen
- U. Köster
- M. Kowalska
- A. L. Lopes
- J.G.M. Correia
- M. Stachura
- T. Stora
- U. Wahl
- *and The ISOLDE collaboration*



SPONSORED BY THE



Federal Ministry
of Education
and Research



Fundação para a Ciência e a Tecnologia
MINISTÉRIO DA CIÊNCIA E DA TECNOLOGIA